VIVUS Inc. (VVUS)
-NasdaqGS | Prev Close: | 14.01 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 17.50 |
|---|
| Beta: | 1.59 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 9.86 - 31.21 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 2,127,620 |
|---|
| Market Cap: | 1.41B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.74 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Consumer Reports Says "Exercise" Rather Than Take This Drugat Motley Fool(Tue, 01:42 SGT)
- InPlay: Vivus: First Manhattan Co issues open letter to Vivus employees urging shareholders to vote for its nominees to the BoardBriefing.com(Mon, 17 Jun)
- Open Letter to Vivus Employees Released by First Manhattan Co.Business Wire(Mon, 17 Jun)
- New Review Article Discusses Complications-Centric Approach to Obesity Medical Management With QsymiaGlobeNewswire(Mon, 17 Jun)
- VIVUS Urges Stockholders to Support the Board of Directors and Management Team at This Critical TimeGlobeNewswire(Mon, 17 Jun)
- The Top 5 Diseases Caused by Obesityat Motley Fool(Mon, 17 Jun)
- Weight loss drug Belviq gets overdue US launchAP(Fri, 7 Jun)
- First Manhattan seeks to replace Vivus directorsAP(Wed, 5 Jun)
- Analysis - A hard day to be a short-seller, one of many this yearat Reuters(Fri, 10 May)
- EU body backs new Roche, Astellas, Sanofi, Vivus drugsReuters(Fri, 26 Apr)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 230.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.44 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | -0.14 |
|---|
Business Summary
VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health.
View More